IQuity Labs, Inc.
NASHVILLE, TN · Founded 2015 · CIK 0001639887 · Biotech · Acquired
Biomarker discovery and testing platform for multiple sclerosis diagnosis, prognosis, and therapy monitoring using long non-coding RNAs (lncRNAs)
decodehealth.ai →- Grants
- $3.9M
- 10 awards
- Sector median: 1
- Raised
- $600K
- 1 Form D · Apr 2015
- 138 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $600,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Long non-coding RNA signatures to classify multiple sclerosis | $159,825 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Long non coding RNA signatures to distinguish fibromyalgia syndrome from rheumatic diseases | $149,286 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Long non-coding RNA signatures to distinguish fibromyalgia syndrome from rheumatic diseases | $149,286 | |
| Federal grant | Department of Health and Human Services · Phase II · Long non-coding RNA signatures to classify multiple sclerosis | $504,933 | |
| Federal grant | Department of Health and Human Services · Phase II · Long non-coding RNA signatures to distinguish fibromyalgia syndrome from rheumatic diseases | $498,258 | |
| Federal grant | Department of Health and Human Services · Phase II · Long non-coding RNA signatures to classify multiple sclerosis | $815,520 | |
| Federal grant | Department of Health and Human Services · Phase II · Long non-coding RNA signatures to distinguish fibromyalgia syndrome from rheumatic diseases | $496,653 | |
| Federal grant | Department of Health and Human Services · Phase II · Long non-coding RNA signatures to track treatment responses in multiple sclerosis | $149,824 | |
| Federal grant | Department of Health and Human Services · Phase II · Long non-coding RNA signatures to track treatment responses in multiple sclerosis | $499,995 | |
| Federal grant | Department of Health and Human Services · Phase II · Long non-coding RNA signatures to track treatment responses in multiple sclerosis | $499,995 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1180 | PRIMAL THERAPIES, INC. | — | $677K |
| 1181 | Grace Bio-Labs, Inc. | — | — |
| 1182 | NEUREXIS THERAPEUTICS, INC. | — | $605K |
| 1183 | IQuity Labs, Inc. | — | $600K |
| 1184 | Immunaeon Inc. | — | $250K |
| 1185 | Exxel Pharma, INC. | — | $600K |
| 1186 | Vivid Genomics, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Julia PolkDirector · Executive Officer
- Charles Spurlock IIIDirector · Executive Officer
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.